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Channelopathies go above and beyond the channels 
 
Since they were first described in the 1990s studies of rare, monogenetic channelopathies have been 
presented as opportunities for understanding more common polygenic disorders. Slightly more than 
two decades after the first descriptions of channelopathies, we use this special issue to re-assess: 
What have we learned from studies of channelopathies? What have channelopathies taught us 
about common diseases?  
 
The assessment begins with a survey of the genetics of channelopathies – not just an extensive 
summary of what is known about mutations in ion channel genes but of potential modifiers and 
accessory subunits (NEUROPHARM-D-17-00087). Because the identities of many ion channel 
interacting proteins are known, channelopathies have played an important role in revealing how 
mutations in related proteins can modify disease severity. Indeed many rare, monogenetic 
channelopaties show distinct polygenic influences in how they manifest. 
 
At a closer level, new structural data allows for exact modelling of how individual mutations change 
the behaviour of the affected channels (NEUROPHARM-D-17-00098). The nature of ion channel 
function means that decades of biophysics has described the function of many channels in detail, 
and these studies are now complemented by molecular dynamics, which can show precisely how the 
changes in channels lead to the changes in function linked to pathology - in at a level of detail which 
geneticists working with proteins of unknown function can only envy. 
 
An additional confounding factor in mapping genotype-phenotype relationships that has emerged 
relatively recently, is that even in some cases when a mutation in an ion channel appears 
pathological, the functional consequences for the channels affected remain elusive. It has become 
apparent that in many cases, post translational processing may be the culprit (NEUROPHARM-D-17-
00127), with mutations that can produce apparently normal channels leading to dysfunctions 
through changes in trafficking (for example). This not only reveals a new mechanism for disease, but 
may reveal new potential angles to treat the changes – by targeting the post translational 
consequences rather than the channel gating itself. 
 
Intimately related to trafficking, is the assembly of complete channels, including subunits that do not 
contribute directly to the pore, but which are necessary for channel function. In this issue we 
highlight the sodium channel β subunits as proteins which can lead to channelopathies 
(NEUROPHARM-D-17-00230), including epilepsy, through mechanisms such as trafficking and 
anchoring, even though they are not directly forming the pore of the channel. The study of 
channelopathies has thus shone a bright light on how mutations in proteins that in heterologous 
systems may not be necessary for protein function, may become functionally critical in the 
endogenous cells. The fact that mutations in β subunits can produce phenocopies of mutations in 
the pore-forming α subunits is a clear demonstration of the requirement for β subunits to produce 
functional channels. 
 
Not all alterations of function are pathological. Ion channels are hugely diverse, and many are 
restricted to different tissues (NEUROPHARM-D-17-00184). Mining the Human Protein Atlas reveals 
the level of tissue specific specialisation of ion channels – with important implications for treatments 
(i.e. an ion channel restricted to cardiac muscle is a poor target for an anti-epileptic treatment). But 
the restrictions are more specific than one gene limited to one tissue. Voltage gated calcium 
channels are used to demonstrate a level of tissue specific expression that is honed down to 
different splice variants dominating in different regions. This opens the potential for splice variant 
specific treatments for tissue specific manifestations of channelopathies. 
 
It is not even the case that all diseases caused by dysfunction of ion channels can be traced to 
mutations in ion channel genes. An important and relatively new family of channelopathies is caused 
by antibodies to ion channels and their associated proteins (NEUROPHARM-D-17-00059). Binding of 
antibodies can disrupt channel function, and trigger immune responses. In these cases, even where 
channel function is known to be disrupted, treatments are clearly targeted at the antibodies, 
including plasma exchange and treatment with steroids. Knowing the antibody based origin of these 
channelopathies makes direct targeting of the dysfunctional channel illogical. 
 
Studies of ion channels have historically relied heavily on the remarkable array of toxins that target 
them (NEUROPHARM-D-17-00311). Toxins have served to identify, purify, functionally characterise, 
and even to name different ion channels. Now new efforts are developing to harness animal toxins 
to treat ion channels that have gone wrong. The high affinity and specificity of toxins – evolved to 
modify channels in order to seriously disrupt excitable cells – is now being used to bind to and in 
some cases restore the function of channels in excitable cells. The approach holds promise so large it 
has not yet been quantified, as the number of toxins and their specificities is remains unknown. 
 
A great advantage of channelopathies is that the function of the disrupted channels can be 
interrogated in real time. Historically this has been done in ex vivo tissue or dissociated cells, where 
mutant and wild type channels can be compared in relative isolation, however recently studies of 
peripheral nerve excitability carried out in patients with mutations in neuronal ion channels, has 
opened a possibility to compare results from reduced preparations to functional consequences in 
functioning neurons in patients (NEUROPHARM-D-17-00086). These studies have the advantage of 
not just corroborating in vitro findings, but also of revealing how neurons adapt to compensate for a 
change in the function of a single type of channel, for example by up- or down-regulating other 
channels. Knowing the compensatory strategies present in vivo might modify mechanistic 
approaches to treatment.  
 
In the final article in this issue, we look forward to new approaches not just to ‘treating’ 
channelopathies, but which raise the possibility of curing them (NEUROPHARM-D-17-00164). Pre-
clinical studies of gene therapy have suddenly emerged from a decade of damage control with 
vigorous, and in many cases impressively effective treatments of monogenetic diseases. The detailed 
biophysical understanding behind channelopathies, including types of functional changes, potential 
compensatory mechanisms, consequences of channel changes on neuronal excitability, means that 
channelopathies offer rich grounds for rational delivery of genes to offset the effects of mutations. 
In addition gene-editing allows the potential to simply repair the mutation. Hurdles in systemic 
delivery, and targeted expression remain, but the extensive data on the functional mechanisms, 
modifications, and successful therapies for channelopathies, means that these are some of the most 
transparent targets for gene therapy and repair.   
 
To return to the original question: what have we learned about neurological disorders from studies 
of channelopathies? They have provided worked examples of how finding a mutation in a gene is 
only the beginning to understanding the mechanism of a disease, and have revealed the many 
possible places – from associated proteins to tissue-specific splicing – to look when a mutation does 
not explain the full clinical manifestations of a disease.   
 
